Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer-Reference-Cited by-同舟云学术

Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer

Published:2022-05 Issue: Volume:166 Page:73-86
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Derksen Jeroen W.G.^ORCID,Smit Karel C.^ORCID,May Anne M.^ORCID,Punt Cornelis J.A.

Funder

Nordic Pharma Group

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016

2. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline;Chiorean;JCO Glob Oncol,2020

3. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer;Hashiguchi;Int J Clin Oncol,2020

4. Effectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: a meta-analysis;Ye;Exp Ther Med,2014

5. Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: a systematic review and meta-analysis;Chen;Medicine (Baltimore),2019

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study);Acta Oncologica;2024-05-02

2. Efficacy and safety of gemcitabine plus raltitrexed or S-1 versus standard third-line therapies in metastatic colorectal cancer: a retrospective cohort study;Journal of Gastrointestinal Oncology;2024-04

3. Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?;Current Treatment Options in Oncology;2024-02-17

4. The Evaluation of Dihydropyrimidine Dehydrogenase Enzyme Level in the Serum of Colorectal Cancer Iraqi Males on Fluoropyrimidine-Based Chemotherapy (Capecitabine);Cureus;2023-09-01

5. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer;ESMO Open;2023-04